Akari Therapeutics announced preclinical data showing their antibody drug conjugate AKTX-101, with a novel RNA spliceosome modulator payload, synergizes with KRAS inhibitors to kill KRAS-mutated pancreatic cancer cells more effectively. This combination demonstrated enhanced cytotoxicity in models with KRAS G12D and G12C mutations, unlike traditional ADCs which showed antagonism. The findings support AKTX-101's potential to improve treatment for difficult KRAS-driven cancers and pave the way for a Phase 1 clinical trial planned for mid-2027. This novel approach targets RNA splicing, offering a new therapeutic strategy beyond current cancer treatments.
AstraZeneca received a 'Strong Buy' rating following robust revenue growth in Q1 2026, driven by 16% and 15% increases in its Oncology and Rare Disease segments, respectively. Key drugs IMFINZI and ULTOMIRIS showed positive phase 3 trial results, ope...
In Q1 2025, Solana achieved a new milestone with 112.6 million average daily non-vote transactions, a 50% increase from the previous quarter, signaling strong user engagement despite market downturns. Launchpad platforms generated $144 million, accou...
Ethereum is at a critical juncture after retesting support near a rising trendline and pushing toward short-term resistance. Analysts highlight that a confirmed breakout above the descending resistance line could first target $2,500, with a stronger ...
StablR's stablecoins EURR and USDR lost their pegs after attackers exploited a weak multisig wallet setup, stealing about $2.8 million worth of crypto. The breach was due to a compromised private key, not a smart contract flaw, allowing hackers to mi...
Advanced Micro Devices (AMD) is emerging as a strong competitor to Nvidia in the AI and data center GPU market. AMD's progress includes achieving CPU parity with Nvidia's Vera, accelerating adoption of its ROCm AI software stack, and developing Helio...
